SEC Form 4 · accession 0001250853-17-000018
Kindred Biosciences, Inc. · KIN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Denise Bevers
Officer — Chief Operating Officer
Period of report
Jan 23, 2017
Accepted (ET)
Jan 25, 2017 · 5:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001561743
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 23, 2017 | A | 100,000 | $0.00 | A | 100,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $6.40 | Jan 23, 2017 | A | 100,000 | A | — | Jan 23, 2027 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1The option will vest as to 25% after one year following the date of grant, and the remainder will vest in equal monthly installments over the following three years, provided Reporting Person remains in continuous employ of the Issuer.